Please enable Javascript
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Ariel DeMaio
Managing Editor
Ariel DeMaio is Managing Editor of
Blood Cancers Today
.
Articles by Ariel DeMaio
The Past, Present, and Future of Venetoclax-Based Therapies in Acute Myeloid Leukemia
Ariel DeMaio
Acute Lymphoblastic Leukemia
|
November 16, 2022
This article reviews the proposed mechanisms of action of venetoclax in AML and the potential future of venetoclax in AML.
Read More
Adding Navitoclax to Ruxolitinib in Persistent or Progressive Myelofibrosis
Ariel DeMaio
Print
|
April 12, 2023
This phase II study enrolled 34 adult patients with intermediate- to high-risk myelofibrosis.
Read More
Could Single-Agent Blinatumomab Take a BiTE Out of B-Cell ALL?
Ariel DeMaio
Acute Lymphoblastic Leukemia
|
February 2, 2023
The chemotherapy-free approach of blinatumomab monotherapy could represent a promising therapy for older adults.
Read More
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant?
Ariel DeMaio
Acute Lymphoblastic Leukemia
|
February 2, 2023
Drs. Short and Webster, discussed their differing views of the current position of transplantation in the treatment of ALL.
Read More
CARs Take Leukemia Patients Closer to a Cure With Decade-Long Remissions
Ariel DeMaio
Chronic Lymphocytic Leukemia
|
February 1, 2023
Two adults who received infusions of anti-CD19 CAR T-cell therapy tisagenlecleucel were in remission at nine and ten years.
Read More
A New Target for Tisagenlecleucel: Primary Central Nervous System Lymphoma
Ariel DeMaio
Print
|
November 29, 2022
Tisagenlecleucel was well-tolerated with manageable toxicity in patients with primary central nervous system lymphoma.
Read More
MRD Negativity Plus Complete Response or Better Associated With Improved PFS in Myeloma
Ariel DeMaio
Myeloma
|
November 14, 2022
Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.
Read More
The Pathology and Pathogenesis of Nodal Peripheral T-Cell Lymphomas
Ariel DeMaio
T-Cell Lymphoma
|
November 14, 2022
Peripheral T-cell lymphomas represent about 10% to 15% of all non-Hodgkin lymphomas.
Read More
Examining the Diversity of Pivotal CAR T-Cell Clinical Trial Enrollment
Ariel DeMaio
Aggressive B-Cell Lymphoma
|
February 1, 2023
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Read More
GLOW: MRD Outcomes After Fixed-Duration Ibrutinib Combinations in Older CLL Patients
Ariel DeMaio
Chronic Lymphocytic Leukemia
|
February 2, 2023
Ibrutinib and venetoclax demonstrated superior MRD responses in older/unfit patients with previously untreated CLL.
Read More
Patients With High-Risk Multiple Myeloma May Be Missed Without Gene Expression Profiling
Ariel DeMaio
Myeloma
|
November 14, 2022
Patients with high-risk myeloma may not be appropriately recognized as having high-risk disease at diagnosis, according to a ...
Read More
Carfilzomib or Bortezomib for Triplet Combination Therapy for Multiple Myeloma?
Ariel DeMaio
Myeloma
|
November 14, 2022
Researchers compared the efficacy of lenalidomide and dexamethasone paired with carfilzomib or bortezomib for the treatment ...
Read More